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pitalization were not 80%, and were higher using prescription-based PDC (92%) than 
interval-based PDC (78%).
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Objectives: To measure the acute-phase persistence and cost of antidepressant 
therapy among commercially insured patients having diabetes. MethOds: We 
conducted a retrospective study among patients with diabetes receiving health 
insurance through Blue Cross & Blue Shield of RI between July 1, 2008–December 
31, 2009. New users of antidepressants were defined as having no history of an 
antidepressant dispensing for at least 90 days preceding an incident antidepressant 
prescription. Patients that continued their medication for at least for 90 days were 
classified as persistent. We compared persistence rates according to the therapeutic 
class of antidepressant prescribed, and by users of brand versus generic products. 
A multivariate logistic regression model was developed to predict non-persistence 
with antidepressant therapy by antidepressant type (SSRI/non-SSRI), and by use 
of generic versus brand products. The average total prescription cost for the 90 
day period was calculated and stratified by use of brand or generic antidepres-
sants. Results: We identified 743 patients with diabetes who were newly pre-
scribed an antidepressant; a majority were prescribed SSRI antidepressants (52.5%), 
while 26% were prescribed a brand name antidepressant, and 432 (58%) patients 
were classified as non-persistent. Users of non-SSRI antidepressants were more 
likely to fail to persist (OR 1.57, 95% CI 1.16-2.12). For non-persistent patients, the 
average cost of therapy was $126.70 among users of brand antidepressants, while 
the average cost among users of generics was $17.10. Among persistent patients, 
the average cost among users of brand antidepressants was $461.4, while the aver-
age cost among users of generics was $70.80. cOnclusiOns: In this population 
of commercially-insured patients having diabetes, acute-phase persistence with 
antidepressant therapy was higher among patients prescribed SSRI medications, 
while treatment costs differed substantially among those prescribed brand versus 
generic medications.
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Objectives: Many retailers offer low cost generic prescriptions, which may mean 
Medicare patients pay cash for at least some Rxs. Plans typically have visibility 
only to adjudicated prescriptions and do not include cash prescriptions in their 
adherence metric. This research investigates whether adherence is actually higher 
than that reported in the Medicare Advantage Star Ratings. MethOds: Adheris® 
receives a nationally representative sample of prescription data, collected directly 
from retail pharmacies, containing roughly 40% of all U.S. retail prescription vol-
ume and 130 million unique patient IDs. The HIPAA-compliant, longitudinal data 
captures all prescriptions filled at the pharmacy, including all payment methods. 
The study cohort selected all patients filling at least one non-cash prescription 
in the oral diabetes category between January and September 2013. Patients were 
observed through December 2013. Exclusion criteria used by CMS for the 2013 Part 
D oral diabetes medication adherence metric were employed. Patient eligibility 
(requiring pharmacy use in the last quarter of the observation period) and a constant 
store panel were utilized to ensure completeness of patient data. Medicaid patients 
were excluded. Adherence was calculated using proportion of days covered (PDC). A 
patient is considered adherent if their PDC> = 80%. PDC computed using only non-
cash prescriptions is compared to PDC computed using all prescriptions (including 
cash) to determine the impact of cash prescriptions on average PDC and on the 
percentage of patients considered adherent. Results: In patients 65+ with at least 
1 cash prescription (n= 62,454), including cash prescriptions improves average PDC 
by 14.89% (64.09-78.98%) and the percentage of adherent patients by 19.38% (40.92-
60.30%). In all patients 65+ (n= 483,740), the improvement is 1.92% (76.45-78.38%) 
and 2.50% (58.16-60.66%) respectively. cOnclusiOns: Including cash prescriptions 
improves adherence rates reported by plans as part of the Star Ratings, indicating 
that patients are more adherent than other statistics indicate.
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Objectives: Dipeptidyl peptidase-4 enzyme inhibitors (DPP-4is) are a class of oral 
antidiabetic medications approved to lower blood glucose in patients with type 2 
diabetes (T2DM). This analysis compared adherence and persistence over 1-year 
and 2-year periods among T2DM patients initiating saxagliptin or sitagliptin, two 
DPP-4is. MethOds: Adults with T2DM in the MarketScan® US claims database who 
initiated saxagliptin or sitagliptin (index drug) between 1/1/2009-1/31/2012 with no 
use of DPP-4is in the previous year were included. 1 year continuous enrollment 
pre-initiation and 1 year post-initiation were required. A sub-group of patients had 
2 years of post-initiation enrollment. Adherence was defined as proportion of days 
covered (adherent if ?0.80), and persistence was defined as time to discontinuation 
(end of days’ supply of index drug prior to gap of 60 days). Logistic regression and 
proportional hazards regression models adjusted for demographic, clinical, and pre-
scription characteristics. Results: 11,219 saxagliptin patients and 49,400 sitagliptin 
patients met the study criteria. The subset with 2 years of follow-up consisted of 
3,505 saxagliptin and 27,568 sitagliptin patients. There were significant differences 
to extremely high daily dose results (skewed distribution). The anomalies were 
addressed by conducting several analyses. The primary analysis included quantities 
from 6-27 ml/day and calculated mg/day DACON values as < 0.6, 0.6-1.5= 1.2, > 1.5-
2.1= 1.8, and > 1.8. Sensitivity analyses were conducted for: (A) all values, (B) quantity 
values “corrected” by corresponding price, (C) quantities corresponding exactly to 
1.2 and 1.8 mg/day, (D) quantities with calculated DACONs between 0.6 and 1.8. 
Additional analyses were performed on excluded patients (N= 30,098). Results: On 
average, patients were 55 years old, 53% female, 60% from PPO plans. Comorbidities 
included hypertension (48%), cardiovascular disease (11%), obesity (10%), and neu-
ropathy (9%). The DACON for primary analysis was 1.64 (34.4% at 1.2 mg/day; 64.2% 
at 1.8 mg/day). A sensitivity analysis of all positive claims (A) produced a DACON 
of 1.97 with 3% of claims > 1.8 mg/day; additional DACON analyses were 1.63(B), 
1.64(C), and 1.59(D). DACON primary analysis and all-value (A) analyses on liraglu-
tide patients not meeting inclusion criteria were 1.65 and 1.95. cOnclusiOns: 
Careful inspection of claims data distributions should guide methods used to 
arrive at reasonable, compelling findings for analyses even as simple as DACON. 
Liraglutide’s DACON in use with type 2 DM ranged from 1.59 to 1.64.
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Objectives: The objective of the study was to measure the health care utiliza-
tion and direct economic burden of diabetic patients covered by urban employee 
basic medical insurance (UEBMI) in urban China. MethOds: All diabetic patients 
enrolled in UEBMI in a sample city from 2009 through 2011 were included. Retrieved 
data included patient personal information, complications and co-morbidities 
(CCs), service utilization, total medical expense and expense reimbursed by the 
scheme. Descriptive analysis was employed to examine the service utilization 
and direct economic burden. Results: There were 1695, 1824, and 2088 diabetic 
patients treated in the schemes from 2009 through 2011, respectively. The propor-
tion of women was around 38% each year. The patients aged 50-80 accounted for 
about 80%. The percentages of chronic CCs increased year by year. Neuropathy, 
hypertension, and cardiovascular and cerebrovascular diseases were the top three 
CCs, accounting for 53.83%, 51.63%, and 28.40% in 2011, respectively. 63%-65% 
patients were managed by only oral glucose-lowering treatments. Each patient had 
the average of 30 outpatient visits and 1.5 hospitalization stays each year. In three 
years, average medical expense per patient was RMB 15,387, 16,817 and 18,714, 
respectively. A little more than 30% of total expenses were paid out-of-pocket by 
patients. Medicines accounted for over 74% of total expenses, but medicines for 
glycemic control only occupied 23%. The top 8 products most used for glucose 
control accounted for 79% of total medicine costs, in which, acarbose and met-
formin were ranked as the first two products, amounting to 34% of total medicine 
costs. cOnclusiOns: Chronic CCs in diabetic patients brought higher medical 
service utilization. Direct economic burden and service utilization increased year 
by year. Medicines was the main expense, but used for other purposes rather than 
glycemic control. The rational use of medicines and CCs monitoring and manage-
ment should be promoted in China.
DiABetes/enDocrine DisorDers – Patient-reported outcomes & Patient 
Preference studies
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Objectives: A number of quality improvement efforts for chronic diseases are 
tied to patients achieving ≥ 80% annual refill adherence. However, there is little 
empirical evidence that this threshold optimally predicts important health out-
comes overall or within different patient sub-groups. The optimal threshold may 
also vary by whether adherence is calculated using interval-based (e.g., measured 
over 365 days) or prescription-based (measured from first through last prescription) 
methods. We used a survival tree model to identify adherence thresholds to oral 
hypoglycemic agents (OHA) most associated with avoidance of hospitalizations in 
different subgroups of diabetes patients. MethOds: We obtained prescription drug 
and medical claims for 30,961 Pennsylvania Medicaid enrollees aged 18-64 years 
with diabetes and ≥ 2 OHA fills, who were continuously enrolled for 30 months 
from 2007-2011 (6 months before and 2 years after their first OHA prescription). 
Adherence rates were calculated during year 1 using interval- and prescription-
based proportion of days covered (PDC). Survival tree models were fit to predict risk 
of all-cause hospitalization in year 2, and empirically identify a series of covariate-
based binary split points to derive adherence thresholds that best discriminate 
hospitalization risk. Results: Among the sample (mean age, 49 years; 67% female), 
mean PDCs were 0.64 (interval-based) and 0.77 (prescription-based). Twenty-four 
percent (n= 7,472) of patients had ≥ 1 hospitalization. Among patients with no base-
line hospitalizations or comorbidities, adherence cut points of 78% (interval-based) 
and 92% (prescription-based) optimally differentiated hospitalization risk, result-
ing in a 20% risk reduction with adherence above these levels. For patients with 
baseline hospitalizations or comorbidities, PDC did not significantly predict future 
hospitalization. cOnclusiOns: Refill adherence thresholds may lack predictive 
validity in terms of hospitalization risk for patients with prior hospitalization or 
comorbidities. For healthier patients, adherence thresholds most predictive of hos-
